NL2035750B1 - Glycogen for supporting tissue viability - Google Patents
Glycogen for supporting tissue viability Download PDFInfo
- Publication number
- NL2035750B1 NL2035750B1 NL2035750A NL2035750A NL2035750B1 NL 2035750 B1 NL2035750 B1 NL 2035750B1 NL 2035750 A NL2035750 A NL 2035750A NL 2035750 A NL2035750 A NL 2035750A NL 2035750 B1 NL2035750 B1 NL 2035750B1
- Authority
- NL
- Netherlands
- Prior art keywords
- tissue
- glycogen
- perfused
- vivo
- scaffold
- Prior art date
Links
- 229920002527 Glycogen Polymers 0.000 title claims abstract description 300
- 229940096919 glycogen Drugs 0.000 title claims abstract description 299
- 230000035899 viability Effects 0.000 title claims abstract description 33
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 20
- 239000007943 implant Substances 0.000 claims abstract description 20
- 230000004083 survival effect Effects 0.000 claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 claims abstract description 11
- 239000003102 growth factor Substances 0.000 claims abstract description 8
- 230000001338 necrotic effect Effects 0.000 claims abstract description 8
- 230000007170 pathology Effects 0.000 claims abstract description 8
- 230000002265 prevention Effects 0.000 claims abstract description 8
- 230000002491 angiogenic effect Effects 0.000 claims abstract description 5
- 210000001519 tissue Anatomy 0.000 claims description 267
- 238000000034 method Methods 0.000 claims description 55
- 239000002245 particle Substances 0.000 claims description 47
- 239000011258 core-shell material Substances 0.000 claims description 34
- 206010021143 Hypoxia Diseases 0.000 claims description 32
- 239000011159 matrix material Substances 0.000 claims description 23
- 235000015097 nutrients Nutrition 0.000 claims description 20
- 210000000056 organ Anatomy 0.000 claims description 19
- 210000000988 bone and bone Anatomy 0.000 claims description 16
- 238000009792 diffusion process Methods 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 241000237502 Ostreidae Species 0.000 claims description 13
- 235000020636 oyster Nutrition 0.000 claims description 13
- 230000001146 hypoxic effect Effects 0.000 claims description 12
- 210000004072 lung Anatomy 0.000 claims description 10
- 210000003205 muscle Anatomy 0.000 claims description 10
- 210000005013 brain tissue Anatomy 0.000 claims description 9
- 210000005003 heart tissue Anatomy 0.000 claims description 9
- 239000007791 liquid phase Substances 0.000 claims description 9
- 210000005228 liver tissue Anatomy 0.000 claims description 9
- 210000004923 pancreatic tissue Anatomy 0.000 claims description 9
- 210000005084 renal tissue Anatomy 0.000 claims description 9
- 210000003491 skin Anatomy 0.000 claims description 9
- 238000002513 implantation Methods 0.000 claims description 6
- 208000037408 Device failure Diseases 0.000 claims description 5
- 230000000735 allogeneic effect Effects 0.000 claims description 5
- 238000010899 nucleation Methods 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- 230000002950 deficient Effects 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 238000010253 intravenous injection Methods 0.000 claims description 3
- 239000012071 phase Substances 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 description 65
- 239000000017 hydrogel Substances 0.000 description 37
- 230000002503 metabolic effect Effects 0.000 description 27
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 23
- 239000008103 glucose Substances 0.000 description 23
- 239000001301 oxygen Substances 0.000 description 23
- 229910052760 oxygen Inorganic materials 0.000 description 23
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 22
- 102000004190 Enzymes Human genes 0.000 description 18
- 108090000790 Enzymes Proteins 0.000 description 18
- 229940088598 enzyme Drugs 0.000 description 18
- 206010002660 Anoxia Diseases 0.000 description 15
- 241000976983 Anoxia Species 0.000 description 15
- 229920002307 Dextran Polymers 0.000 description 15
- 230000007953 anoxia Effects 0.000 description 15
- 102000007390 Glycogen Phosphorylase Human genes 0.000 description 14
- 108010046163 Glycogen Phosphorylase Proteins 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 238000001727 in vivo Methods 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 230000003833 cell viability Effects 0.000 description 13
- 150000002978 peroxides Chemical class 0.000 description 11
- 239000007787 solid Substances 0.000 description 10
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 9
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 9
- 210000002744 extracellular matrix Anatomy 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 239000008107 starch Substances 0.000 description 9
- 235000019698 starch Nutrition 0.000 description 9
- 230000015556 catabolic process Effects 0.000 description 8
- 238000006731 degradation reaction Methods 0.000 description 8
- 239000002207 metabolite Substances 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 230000033115 angiogenesis Effects 0.000 description 7
- 239000002870 angiogenesis inducing agent Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 230000001023 pro-angiogenic effect Effects 0.000 description 7
- 230000009772 tissue formation Effects 0.000 description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 230000007954 hypoxia Effects 0.000 description 5
- 230000010412 perfusion Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000003511 endothelial effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- 230000025366 tissue development Effects 0.000 description 4
- 108090000344 1,4-alpha-Glucan Branching Enzyme Proteins 0.000 description 3
- 102000003925 1,4-alpha-Glucan Branching Enzyme Human genes 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000000919 ceramic Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 108010001483 Glycogen Synthase Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 108020000005 Sucrose phosphorylase Proteins 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- DZGWFCGJZKJUFP-UHFFFAOYSA-N Tyramine Natural products NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 231100000031 angiotoxic Toxicity 0.000 description 2
- 230000002283 angiotoxic effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000010256 biochemical assay Methods 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 235000021232 nutrient availability Nutrition 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 239000004632 polycaprolactone Substances 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 230000008467 tissue growth Effects 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 229960003732 tyramine Drugs 0.000 description 2
- DZGWFCGJZKJUFP-UHFFFAOYSA-O tyraminium Chemical compound [NH3+]CCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-O 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- NGDLSKPZMOTRTR-OAPYJULQSA-N (4z)-4-heptadecylidene-3-hexadecyloxetan-2-one Chemical compound CCCCCCCCCCCCCCCC\C=C1/OC(=O)C1CCCCCCCCCCCCCCCC NGDLSKPZMOTRTR-OAPYJULQSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- BGWLYQZDNFIFRX-UHFFFAOYSA-N 5-[3-[2-[3-(3,8-diamino-6-phenylphenanthridin-5-ium-5-yl)propylamino]ethylamino]propyl]-6-phenylphenanthridin-5-ium-3,8-diamine;dichloride Chemical compound [Cl-].[Cl-].C=1C(N)=CC=C(C2=CC=C(N)C=C2[N+]=2CCCNCCNCCC[N+]=3C4=CC(N)=CC=C4C4=CC=C(N)C=C4C=3C=3C=CC=CC=3)C=1C=2C1=CC=CC=C1 BGWLYQZDNFIFRX-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010013647 Drowning Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000005313 bioactive glass Substances 0.000 description 1
- 239000003364 biologic glue Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000003592 biomimetic effect Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000004956 cell adhesive effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000002241 glass-ceramic Substances 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- -1 glycogen Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 108010085781 maltodextrin phosphorylase Proteins 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000009443 proangiogenesis Effects 0.000 description 1
- 238000012342 propidium iodide staining Methods 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000002174 soft lithography Methods 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Materials For Medical Uses (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (27)
1. Gebruik van glycogeen voor het behouden van levensvatbaarheid (viability) van niet- geperfundeerd of sub-optimaal geperfundeerd weefsel, waarbij het gebruik het combineren van het weefsel en het glycogeen omvat, waarbij het gebruik ex vivo is.
2. Gebruik van glycogeen voor het verlengen van overlevingstijd van een niet- geperfundeerde of sub-optimaal geperfundeerde weefselstructuur, waarbij het gebruik het combineren van de weefselstructuur en het glycogeen omvat, waarbij het gebruik ex vivo is.
3. Gebruik van glycogeen voor het voorkomen van necrotische kernvorming in een niet- geperfundeerde of sub-optimaal geperfundeerde weefselstructuur, waarbij het gebruik het combineren van de weefselstructuur en het glycogeen omvat, waarbij het gebruik ex vivo is.
4. Gebruik van glycogeen voor het verhogen van productie van angiogene groeifactoren door niet-geperfundeerd weefsel, waarbij het gebruik het combineren van het weefsel en het glycogeen omvat, waarbij het gebruik ex vivo is.
5. Glycogeen voor gebruik bij de preventie of behandeling van weefselimplantaatfalen bij een patiënt, waarbij bij het gebruik het glycogeen in combinatie met het weefselimplantaat is.
6. Glycogeen voor gebruik bij de preventie of behandeling van een aandoening gekenmerkt door aanwezigheid van niet-geperfundeerd of of sub-optimaal geperfundeerd weefsel, bij voorkeur hypoxisch en/of nutrient-deficiént weefsel.
7. Glycogeen voor gebruik volgens conclusie 6, waarbij het glycogeen wordt toegediend door middel van lichaam injectie, bij voorkeur intraveneuze injectie, en/of waarbij het glycogeen bij gebruik in combinatie is met het genoemde weefsel.
8. Glycogeen voor gebruik bij de behandeling van een weefselpathologie bij een patiënt, waarbij bij het gebruik het glycogeen in combinatie is met vervangend weefsel en/of scaffold voor weefselingroei, en waarbij het gebruik het inbrengen van het vervangende weefsel en/of de scaffold in de patiënt omvat, en waarbij het glycogeen betrekking heeft op glycogeendeeltjes met een gemiddelde diameter van 30-1000 nm, bij voorkeur oesterglycogeen.
9. Glycogeen voor gebruik volgens één van de conclusies 5-8, waarbij het weefsel botweefsel, orgaanweefsel, nierweefsel, leverweefsel, hartweefsel, longweefsel, pancreasweefsel, spierweefsel, hersenweefsel, of huidweefsel is en/of waarbij het weefsel autoloog, allogeen of xenogeen is voor de patiënt.
10. Glycogeen voor gebruik volgens één van de conclusies 5-9, waarbij het glycogeen is ingekapseld door een matrixmateriaal met een netwerk met een gemiddelde maaswijdte die diffusie van het glycogeen voorkomt, bij voorkeur is het glycogeen omvat in holtes in genoemd matrixmateriaal, waarbij de holtes een gemiddeld volume van ten minste 100 nm? hebben.
11. Glycogeen voor gebruik volgens één van de conclusies 5-10, waarbij het glycogeen in een vloeibare fase in een core-shell deeltje is omvat.
12. Glycogeen voor gebruik volgens één van de conclusies 5-11, waarbij het glycogeen aanwezig is in een samenstelling of vloeistof in een hoeveelheid tussen 0,1-100 g/L, bij voorkeur tussen 1-20 g/L.
13. Ex vivo werkwijze voor het vormen van weefsel, de werkwijze omvattende a) het zaaien van een scaffold met cellen die weefsel kunnen vormen, waarbij de scaffold in combinatie is met glycogeen en waarbij het glycogeen betrekking heeft op glycogeendeeltjes met een gemiddelde diameter van 30-1000 nm, bij voorkeur oesterglycogeen; b) het kweken van de cellen onder omstandigheden die geschikt zijn om weefsel op en/of in de scaffold te laten groeien.
14. Werkwijze volgens claim 13, waarbij het glycogeen wordt ingekapseld door een matrixmateriaal met een netwerk met een gemiddelde maaswijdte die diffusie van het glycogeen voorkomt, bij voorkeur is het glycogeen omvat in holtes in genoemd matrixmateriaal, waarbij de holtes een gemiddeld volume van ten minste 100 nm? hebben.
15. Methode volgens één van de conclusies 13-14, waarbij het glycogeen in een vloeibare fase in een core-shell deeltje is omvat.
16. Werkwijze volgens één van de conclusies 13-15, waarbij het glycogeen aanwezig is in een samenstelling of vloeistof in een hoeveelheid tussen 0,1-100 g/L, bij voorkeur tussen 1- 20 g/L.
17. Werkwijze volgens één van de conclusies 13-18, waarbij het weefsel betrekking heeft op botweefsel, orgaanweefsel, nierweefsel, leverweefsel, hartweefsel, longweefsel, pancreasweefsel, spierweefsel, hersenweefsel, of huidweefsel.
18. Ex vivo werkwijze voor het bereiden van een weefsel voor implantatie bij een patiënt, waarbij de werkwijze omvat a) het verstrekken van een weefsel; b) het combineren van het weefsel met glycogeen en waarbij het glycogeen betrekking heeft op glycogeendeeltjes met een gemiddelde diameter van 30-1000 nm, bij voorkeur oesterglycogeen.
19. Werkwijze volgens conclusie 18, waarbij het weefsel is botweefsel, orgaanweefsel, nierweefsel, leverweefsel, hartweefsel, longweefsel, pancreasweefsel, spierweefsel, hersenweefsel, huidweefsel en/of waarbij het weefsel autoloog, allogeen of xenogeen is voor de patiënt.
20. Methode volgens één van de conclusies 18-19, waarbij het glycogeen is ingekapseld door een matrixmateriaal met een netwerk met een gemiddelde maaswijdte die diffusie van het glycogeen voorkomt, bij voorkeur is het glycogeen omvat in holtes in genoemd matrixmateriaal, waarbij de holtes een gemiddeld volume van ten minste 100 nm? hebben.
21. Methode volgens één van de conclusies 18-20, waarbij het glycogeen zich in een vloeibare fase in een core-shell deeltje is omvat.
22. Werkwijze volgens één van de conclusies 18-21, waarbij het glycogeen aanwezig is in een vloeistof in een hoeveelheid tussen 0,1-100 g/L, bij voorkeur tussen 1-20 g/L.
23. Ex vivo weefselstructuur en/of scaffold voor weefselingroei, in combinatie met glycogeen, waarbij - het glycogeen aanwezig is in samenstelling of vloeibaar in een hoeveelheid tussen 0,1-100 g/L, bij voorkeur tussen 1-20 g/L; of - het glycogeen heeft betrekking op glycogeendeeltjes met een gemiddelde diameter van 30- 1000 nm, bij voorkeur oesterglycogeen.
24. Ex vivo weefselstructuur volgens conclusies 23, waarbij het weefsel betrekking heeft op botweefsel, orgaanweefsel, nierweefsel, leverweefsel, hartweefsel, longweefsel, pancreasweefsel, spierweefsel, hersenweefsel, of huidweefsel.
25. Ex vivo weefselstructuur en/of scaffold volgens één van de conclusies 23-24, waarbij het glycogeen is ingekapseld door een matrixmateriaal met een netwerk met een gemiddelde maaswijdte die diffusie van het glycogeen voorkomt, bij voorkeur is het glycogeen omvat in holtes in genoemd matrixmateriaal, waarbij de holtes een gemiddeld volume van ten minste 100 nm3 hebben.
26. Ex vivo weefselstructuur volgens één van de conclusies 23-25, waarbij het glycogeen zich in een vloeibare fase in een core-shell deeltje is omvat.
27. Ex vivo weefselstructuur volgens één van de conclusies 23-28, waarbij het glycogeen aanwezig is in een vloeistof in een hoeveelheid tussen 0,1-100 g/L, bij voorkeur tussen 1-20 g/L.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2035750A NL2035750B1 (en) | 2023-09-06 | 2023-09-06 | Glycogen for supporting tissue viability |
| PCT/EP2024/074782 WO2025051833A1 (en) | 2023-09-06 | 2024-09-05 | Glycogen for supporting tissue viability |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2035750A NL2035750B1 (en) | 2023-09-06 | 2023-09-06 | Glycogen for supporting tissue viability |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL2035750B1 true NL2035750B1 (en) | 2025-03-13 |
Family
ID=88413975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL2035750A NL2035750B1 (en) | 2023-09-06 | 2023-09-06 | Glycogen for supporting tissue viability |
Country Status (2)
| Country | Link |
|---|---|
| NL (1) | NL2035750B1 (nl) |
| WO (1) | WO2025051833A1 (nl) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08198758A (ja) * | 1995-01-24 | 1996-08-06 | Aomori Pref Gov | グリコーゲンの癌予防剤としての用法 |
-
2023
- 2023-09-06 NL NL2035750A patent/NL2035750B1/en active
-
2024
- 2024-09-05 WO PCT/EP2024/074782 patent/WO2025051833A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08198758A (ja) * | 1995-01-24 | 1996-08-06 | Aomori Pref Gov | グリコーゲンの癌予防剤としての用法 |
Non-Patent Citations (9)
| Title |
|---|
| ADAM: "The influence of the glycogen content of the donor liver on subsequent graft functions and survival in rat liver transplantation", TRANSPLANTATION, vol. 54, 1 January 1992 (1992-01-01), pages 753 - 756, XP093155897 * |
| ANDREA GÁLISOVÁ: "Glycogen as an advantageous polymer carrier in cancer theranostics: Straightforward in vivo evidence", SCIENTIFIC REPORTS, vol. 10, no. 1, 26 June 2020 (2020-06-26), US, XP093155505, ISSN: 2045-2322, Retrieved from the Internet <URL:https://www.nature.com/articles/s41598-020-67277-y> DOI: 10.1038/s41598-020-67277-y * |
| ANON.: "Glycogen - Wikipedia", 18 March 2023 (2023-03-18), pages 1 - 11, XP093155498, Retrieved from the Internet <URL:https://web.archive.org/web/20230318034245/https://en.wikipedia.org/wiki/Glycogen> * |
| BIN DENG: "Molecular Structure of Human-Liver Glycogen", PLOS ONE, vol. 11, no. 3, 2 March 2016 (2016-03-02), US, pages e0150540, XP093156026, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0150540 * |
| EDGARDO E. GUIBERT ET AL: "Organ Preservation: Current Concepts and New Strategies for the Next Decade", TRANSFUSION MEDICINE AND HEMOTHERAPY, vol. 38, no. 2, 1 January 2011 (2011-01-01), pages 125 - 142, XP055158789, ISSN: 1660-3796, DOI: 10.1159/000327033 * |
| MAUD BESSEMS ET AL: "Improved machine perfusion preservation of the non-heart-beating donor rat liver using polysol: A new machine perfusion preservation solution", LIVER TRANSPLANTATION, vol. 11, no. 11, 19 October 2005 (2005-10-19), US, pages 1379 - 1388, XP055283300, ISSN: 1527-6465, DOI: 10.1002/lt.20502 * |
| RANDY P PULIS ET AL: "A Metabolic Mechanism for the Detrimental Effect of Exogenous Glucose During Cardiac Storage", AMERICAN JOURNAL OF TRANSPLANTATION, BLACKWELL MUNKSGAARD, DK, vol. 3, no. 8, 30 June 2003 (2003-06-30), pages 961 - 967, XP072340087, ISSN: 1600-6135, DOI: 10.1034/J.1600-6143.2003.00166.X * |
| WILLEMENNIELS GA ET AL., ADVANCED HEALTHCARE MATERIALS, vol. 11, no. 13, 2022, pages 2102697 |
| ZARGARZADEHMEHRZAD ET AL.: "Self-glucose feeding hydrogels by enzyme empowered degradation for 3D cell culture", MATERIALS HORIZONS, vol. 9, no. 2, 2022, pages 694 - 707 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2025051833A1 (en) | 2025-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Keane et al. | Biomaterials for tissue engineering applications | |
| US7815686B2 (en) | Vascularization enhanced graft constructs | |
| US9456893B2 (en) | Engineered tissue implants and methods of use thereof | |
| Farris et al. | Oxygen delivering biomaterials for tissue engineering | |
| Czaja et al. | The future prospects of microbial cellulose in biomedical applications | |
| US5759830A (en) | Three-dimensional fibrous scaffold containing attached cells for producing vascularized tissue in vivo | |
| KR102311639B1 (ko) | 심근조직 재생용 3차원 구조체의 제조방법 | |
| US20110040388A1 (en) | Biocompatible implant | |
| BR102019014873A2 (pt) | Processo de obtenção de um substituto dérmico funcional a partir de membrana amniótica descelularizada proveniente de placenta em combinação com queratinócitos e seu uso como agente de regeneração tissular de pele | |
| US20090136553A1 (en) | Triggerably dissolvable hollow fibers for controlled delivery | |
| Andleeb et al. | Hydrogel patch with pretreated stem cells accelerates wound closure in diabetic rats | |
| RU2425645C1 (ru) | Способ и трансплантат для лечения печеночной недостаточности | |
| NL2035750B1 (en) | Glycogen for supporting tissue viability | |
| Yunkun et al. | Biomaterial scaffolds for improving vascularization during skin flap regeneration | |
| US20230174942A1 (en) | Novel fabrication of coronary based decellularized heart flaps to treat aneurysm following myocardial infarction | |
| US10149865B2 (en) | Method for preparing a biological tissue construct and use of autologous cells obtained specifically | |
| Sugiura et al. | Tissue engineering in vascular medicine | |
| Tezcaner et al. | Fundamentals of tissue engineering: tissues and applications | |
| RU2425646C1 (ru) | Способ и трансплантат для лечения печеночной недостаточности | |
| Modulevsky | Plant derived cellulose scaffolds as a novel biomaterial for 3d cell culture and tissue regeneration | |
| Sundaram et al. | Tissue engineering and regenerative medicine | |
| Quint et al. | Tissue engineering and regenerative medicine | |
| Obulapuram et al. | Role of natural cellulose and hydrogel matrices in stem cell therapy of diabetic foot ulcer | |
| CN119868659A (zh) | 一种人工重塑大网膜 | |
| El Hajj | Porous hydrogel promoting spontaneous organoid formation for bone reconstruction: implementation in a perfusion bioreactor |